EPAM Acquires Odysseus — to transform the Life Sciences Value Chain with Advanced Analytics, Data Methods and AI
Summary
With their strong capabilities in Real-World Evidence and Real-World Data — the ‘glue’ between multiple segments of the life sciences value chain — our natural synergies make this an exciting time to add this to our portfolio to help our clients achieve better outcomes,” said Greg Killian, Senior Vice President of Life Sciences at EPAM. “We see the next wave of innovation based on standardized data powering AI and GenAI to improve life sciences research, clinical studies and post-market surveillance. We deliver globally, but engage locally with our expert teams of consultants, architects, designers and engineers, making the future real for our clients, our partners and our people around the world. Those future events and trends may relate to, among other things, developments relating to the war in Ukraine and escalation of the war in the surrounding region, political and civil unrest or military action in the geographies where we conduct business and operate, difficult conditions in global capital markets, foreign exchange markets and the broader economy, and the effect that these events may have on customer demand and our revenues, operations, access to capital, and profitability. EPAM undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.